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Securing access to eﬀective antimicrobials is one of the greatest challenges today. Until now, eﬀorts to address this
issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global
collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued
innovation. Access, conservation, and innovation are beneﬁcial when achieved independently, but much more
eﬀective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive
these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global
coordination, and ﬁnancing mechanisms with suﬃcient mandates, authority, resources, and power. Fortunately,
securing access to eﬀective antimicrobials has ﬁnally gained a place on the global political agenda, and we call on
policy makers to develop, endorse, and ﬁnance new global institutional arrangements that can ensure robust
implementation and bold collective action.

Introduction
This Lancet Series has argued that both inadequate access
to antimicrobials and antimicrobial resistance are
daunting threats to both human and animal health—ie, a
One Health approach is necessary to address these issues.1
The most cost-eﬀective and time-eﬃcient method is to
protect the usefulness and longevity of existing

Key messages
• Global collaboration is necessary to improve access to antimicrobials and sustain their
eﬀectiveness. Although this is well known and accepted, present collaborative eﬀorts
remain far too modest and poorly funded.
• Interlinked global collaboration is needed in the policy areas of universal access,
responsible use, and innovation. Increasing innovation and global access without
responsible use provisions might increase the emergence of resistance. Strengthened
eﬀorts towards responsible use could lead to smaller and less lucrative markets, thus
dampening innovation and possibly impeding access. To avoid improper incentives
to waste antimicrobials, payments for antimicrobials should be delinked from the
volumes sold.
• WHO cannot successfully tackle this problem on its own. Because of the multisectoral
nature of the problem—requiring action across the health, agriculture, and veterinary
sectors—and the need to build new business models for antimicrobial innovation and
use, multisectoral coordination under a One Health model is necessary to bring about
action and real change.
• Global actions to address this challenge need to be a combination of quick wins and
long-term eﬀorts. For example, a few large markets could agree to restrict certain
classes of antimicrobials only to human use while a formal global mechanism is being
negotiated and adopted. This combination of short-term and long-term strategies
needs to be taken for each policy area—namely, surveillance, universal access,
infection prevention, responsible use, and innovation.
• Global coordination and ﬁnancing mechanisms need to be improved. Two leading
institutional options are a new UN-level coordinating body and an international
treaty with strong implementation mechanisms.
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antimicrobials, while continuing research into new
vaccines, drugs, and related technologies, for much is still
to be learnt about the mechanisms of infection and
resistance.2 The starting point for any concerted policy
action should be to expand access to life-saving
antimicrobials worldwide, recognising that some parts of
the world still face issues of poor sanitation and inadequate
access to antimicrobials.3 However, expansion of access
needs to be linked to improved approaches for combating
resistance. Evidence shows that many interventions can
be eﬀective at national levels,4 but their implementation
also requires global vigilance and action.
Coordination across sectors is necessary to preserve
antimicrobial eﬀectiveness. Gains in combating resistance
through health-care interventions might be undercut by
proliﬁc use in agricultural settings. Strong conservation
eﬀorts, although medically appropriate, might hamper the
business case for innovation that leads to new therapies.
Boosting access without stewardship measures could
drive resistance. Thus, although many actions can be
taken independently at the national and sectoral levels,
they will be more eﬀective if coordinated globally across
all relevant sectors and stakeholders.5
The complex policy challenges of improving access to
and sustaining eﬀectiveness of antimicrobials warrant
interventions in several areas. This Lancet Series has used
a framework spanning the breadth of policy goals
needed.4 Improved surveillance and monitoring are
crucial to obtain information on the present situation and
progress.4 Universal access to antimicrobials needs to be
a primary goal in all countries progressing towards
universal health coverage.3 However, the need for
antimicrobials can be lessened through improved
infection control, and their use can become more
appropriate by reducing misuse and overuse through
www.thelancet.com Vol 387 January 16, 2016
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interventions that decrease both supply and demand.3,4
Progress towards these goals will rely on raised awareness
among the public and all relevant stakeholders (eg, policy
makers and health-care personnel).4 Advances also need
to build on an expanded knowledge base, through
innovation and research and development (R&D), to
achieve an increased understanding of mechanisms and
drivers of resistance,2 develop new technologies,3 and
design, implement, and assess interventions.4 The control
and reduction of resistance are public goods—ie,
achievements in which all stand to beneﬁt. However, with
increasing antimicrobial resistance in low-income and
middle-income countries (LMICs),1 these nations will
struggle to ﬁnance the implementation of these policies,
and ﬁnancial assistance will be key to global success.
In this last paper of the Series, we analyse how countries
and other stakeholders need to work together to achieve
these key policy goals. We identify existing gaps in
international cooperation, recommend actions to improve
collaboration, and discuss how the resulting policies
could be packaged for adoption and implementation.

Strengthening international collaboration
We reviewed all World Health Assembly resolutions and
documentation related to antimicrobial resistance, in
addition to related scientiﬁc literature published in
2012–15, to identify core high-level policy areas—namely,
surveillance, universal access, responsible use, infection
control, and innovation. Improved implementation
across these policy areas is needed to ensure sustainable
access to eﬀective antimicrobials. Together with the
other papers in this Series,1–4 we identiﬁed important
gaps in international collaboration in each of the ﬁve
policy areas (panel). However, the level of collaboration
necessary to ensure success will diﬀer from policy to
policy. On the basis of the 5C Framework (ﬁgure),
previously used to analyse human resources for health,6
we assessed the minimum level of collaboration needed
for a policy to achieve its goal and the relevant
international policies (table 1).
Some global policy objectives can be met by
collaborative mechanisms that help to set common
norms, principles, and goals. This is the lowest level of
collaboration in the 5C Framework, one that is often
eﬀectively fulﬁlled by UN entities and exempliﬁed
by WHO’s resolutions on antimicrobial resistance.1
However, higher levels of collaboration are necessary for
other objectives. For example, another function of WHO
is to facilitate communication, which includes sharing
of information and data between countries—eg,
dissemination of guidance and educational material on
appropriate disease management and treatment
regimens.3 Coordination is essential for eﬀective global
surveillance systems and for the uptake of adequate
infection control procedures.3,4 Other objectives—eg,
promotion of universal access, responsible use, and
innovation—will need even higher levels of collaboration,

Panel: Gaps in international collaboration
• Surveillance—no global database exists for antimicrobial
resistance or use, meaning that identiﬁcation of
surveillance gaps is diﬃcult or impossible. No publicly
available registry of laboratory capacity by country exists.
Surveillance data are rarely recorded in real time or
globally compatible in format.
• Infection control—a common repository for evidence of
infection prevention measures is absent. Substantial
ﬁnancing and technical assistance is needed to help
low-income and middle-income countries (LMICs) to
implement evidence-based national infection
prevention programmes.
• Universal access—no internationally agreed mechanisms
exist to ensure aﬀordability in LMICs. Financing to
support improved access to antibiotics is restricted.
• Responsible use in human beings—the framework to
restrict marketing of antimicrobials has not been agreed.
Capacities to enforce existing regulations are insuﬃcient,
and no internationally agreed quality measures for
optimum prescribing exist.
• Responsible use in animals—no global mechanisms exist
to reduce inappropriate use in animal husbandry or
restrict speciﬁc classes to human use only. Europe is the
only region that have banned the use of antibiotics in
livestock and agriculture as growth promoters or for
disease prevention.
• Innovation—existing incentives are not well aligned to
responsible use policies. The bulk of these initiatives were
not developed with the needs of LMICs in mind. The scale
of these initiatives is insuﬃcient to ensure the
development of new antimicrobials, diagnostics, vaccines,
or related technologies that target unmet medical needs.

including collaborative decisions and, at the highest
level, collective action (ﬁgure). Such international
collaboration is necessary to ensure the success of many
policies that improve access to and sustain eﬀectiveness
of antimicrobials (table 1).

Surveillance
Two related issues of surveillance are collection and
reporting of data, and strengthening of laboratory
capacity. WHO ﬁrst passed a resolution in 1998 urging
Member States to develop surveillance systems for
antimicrobial agents.7 Despite the WHO global strategy
for containment of antimicrobial resistance (2001) and
recurrent calls to improve these global surveillance
eﬀorts, little progress has been made in the past 15 years.8
Worryingly, the ﬁrst antimicrobial resistance global
report on surveillance (2014) of existing national systems9
showed that only 22 countries were able to report on all
nine bacterial species of international concern. However,
114 of the 129 countries who reported their status
obtained data for at least one species.

www.thelancet.com Vol 387 January 16, 2016
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V
Collective
action

IV
Collaborative
decisions

III
Coordination

II
Communication

I
Common norms, principles, and goals

To what extent does the policy require binding multinational
decisions (eg, through joint institutional arrangements
or pooled financing)?

To what extent does the policy require multinational
collaborative decision making (eg, through joint strategies)?

To what extent does the policy require coordination
of individual countries’ decision making?

To what extent does the policy require eﬀective
sharing of information and data?

To what extent does the policy require common
norms, principles, and goals to be shared and agreed
across organisations and governments?

Figure: The 5C Framework—assessment of minimum collaboration needed for a successful policy
This framework can be used to assess the minimum level of collaboration needed for a policy to deliver its stated goal. It is hierarchical—ie, level V (collective action)
requires greater collaboration than level IV (collaborative decisions) and so on.

To comply with the International Health Regulations
(IHR; 2005), each government is required to have access
to laboratory services and obliged to report to WHO.10 At
the WHO Executive Board Meeting in January, 2014,
only 23 Member States were reported to be fully
compliant with the IHR’s laboratory requirements.11
This self-reporting shows that many Member States,
across all income categories, are struggling with the
laboratory capacities stipulated by the IHR. Since these
capacities are more comprehensive than those necessary
for antimicrobial resistance surveillance, the actual
magnitude of inadequate laboratory capacity directly
related to antimicrobial resistance is unknown at
present. In 2011, three UN agencies—WHO, World
Organisation for Animal Health (OIE), and the Food and
Agriculture Organization (FAO)—jointly initiated
several collaborative projects that aimed to strengthen
laboratory capacity. These projects included capacity
building for compliance with laboratory quality
standards, the development of international networks,
and laboratory twinning initiatives.12
A global surveillance system is essential to improve
access to and sustain the eﬀectiveness of antimicrobials.4
The communication of surveillance data can help to
identify patterns of resistance and focus on necessary
support. This is not a call for a new global super system
but rather a coordinated eﬀort to obtain data from
present functioning systems, implement appropriate
systems in countries without existing ones, report these
data, and highlight the gaps annually. These data
298

include the use of antimicrobials (in human beings and
livestock, and for other agricultural purposes), the
prevalence of antimicrobial resistance, and laboratory
capacity, all by country, in a standard way so that valid
comparisons can be made. This coordination will
require cross-sectoral focus bridging the FAO, OIE, and
WHO. To accurately report prevalence data, national
and regional laboratory capacity has to be strengthened.
Capacity-building plans, including technical and
ﬁnancial support, should be created for countries that
are unable to report these data. As this function matures
and as countries improve their reporting, interoperability
and minimum data standards can be implemented.

Infection control
Many infection control collaborations are at work across
the globe through local, national, regional, and
international networks, as detailed by Dar and colleagues
in this Lancet Series.4 However, many of these collaborations
are underfunded. LMICs are lagging behind high-income
countries, predominantly because of inadequate ﬁnancial
resources necessary for good infection control.13
National infection prevention programmes are the
mandate of governments, but external supportive
ﬁnancing of these eﬀorts in LMICs should continue.
These eﬀorts should be linked to surveillance data so that
those countries reporting increasing resistance levels or
inappropriate use can receive technical and ﬁnancial
assistance to reverse these trends. On a global basis, it
might be more eﬃcient to speed the adoption of basic
www.thelancet.com Vol 387 January 16, 2016
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Level of cooperation—5C assessment
Surveillance
Develop mechanisms for
surveillance data collection
and reporting

Communication (level II)—surveillance information needs to be shared internationally. Eﬀorts have already been attempted with
common norms, principles, and goals. Each of the four WHO resolutions from 1998 to 2014 has urged Member States towards
heightened surveillance.
Coordination (level III)—a global agreement on an international data collection mechanism is needed to ensure that countries are
tracking key drug–bug combination data and using common standards. With a global system, countries that are yet to achieve fully
developed monitoring systems can be rapidly identiﬁed and oﬀered assistance. As this reporting process matures, interoperability
and reporting standards will become important. Surveillance data will need to be centrally stored, analysed, and monitored for
gaps. Data should have the potential to be aggregated to allow for meaningful analyses of resistance on a large scale, and a
cross-sectoral focus bridging FAO, OIE, and WHO is necessary.

Build laboratory capacity and
implement regionally

Coordination (level III)—donors and governments need to jointly prioritise ﬁnancing and technical capacity building to improve
national and regional laboratories. For countries without suﬃcient laboratory capacity, at a minimum, a plan should be developed
and ﬁnanced to oﬀer either a national or a regional solution. WHO has been delivering on common norms, principles, and goals of
best practices for laboratories and communicating these to Member States. Two of the four WHO resolutions urge Member States
to improve laboratory capacity building. A higher level of collaboration is needed.

Infection control
Finance and generate
evidence of infection
prevention and control
interventions

Communication (level II)—evidence of eﬀective interventions is a global public good to be shared, summarised, and promoted to
stakeholders and policy makers.
Coordination (level III)—LMICs might need ﬁnancial assistance to implement suﬃcient interventions. Donors need to jointly
prioritise the ﬁnancing of eﬀective infection prevention measures, such as improved hygiene practices and immunisation, for
countries with few ﬁnancial resources.

Universal access
Ensure that eﬀective
antimicrobials are equitably
accessible

Coordination (level III)—donors and governments need to jointly prioritise universal access to antimicrobials as a basic step
towards achieving universal health coverage. Insuﬃcient access in LMICs is a market failure and requires corrective action, such as
the international assistance (both ﬁnancial and technical) provided through the Global Fund to Fight AIDS, Tuberculosis and
Malaria.
Collaborative decisions (level IV)—strengthening of health services and systems to provide universal access to antimicrobials needs
to happen at the national level. However, global-level facilitators are needed to ensure aﬀordability in LMICs.

Responsible use in human beings
Develop mechanisms for
responsible marketing, sales,
and use

Collaborative decisions (level IV)—although regulations are a national responsibility and prerogative, the global market of
antimicrobials crosses many borders. As a result, common standards and practices that are regularly communicated are necessary.
These internationally agreed policies could take the form of either self-regulatory codes of practices or a binding legal agreement.
Coordination (level III)—although the regulation of medical practice is a core national responsibility, information on best practices
for responsible use should be created and shared broadly, with appropriate adjustments showing available resources in the
health system.

Responsible use in agriculture
Restrict speciﬁc classes of
antimicrobials to human
use only

Collaborative decisions (level IV) or collective action (level V)—each country will need to pass eﬀective laws to implement these
restrictions. In the short term, incentives could be given to patent holders and generic-drug producers, rewarding them for sales
restriction. Global enforcement of this policy necessitates either collaborative decisions or collective action. This policy will only be
successful if it is consistently implemented and regulated worldwide.

Reduce the use of antibiotics
for growth promotion and
disease prevention in animals

Collaborative decisions (level IV) or collective action (level V)—although each country needs to determine how it will reduce the
use of antibiotics for growth promotion, collaboration is needed to ensure that the reduction is sizeable enough to make a
diﬀerence and to avoid free riding. Global collective action is probably the best way to avoid free riding in countries where
antimicrobial misuse continues. To be eﬀective, compliance incentives or penalty for countries, perhaps through a global legal
instrument, are necessary.

Innovation
Finance priority R&D that is
stipulated on responsible use
provisions

Collaborative decisions (level IV) or collective action (level V)—R&D costs are larger than those bearable by any one country, but
substantial progress could be made with leadership from groups such as the G7, G20, and BRICS. Collaboration on both ﬁnancing
and R&D activities is necessary. Usually, ﬁnancing could be done through governmental coordination (level III); however, the
allocation of this ﬁnancing for new antimicrobials, vaccines, and diagnostics should be bound to restrictions that promote
responsible use and therefore require enforcement, meaning that a higher level of collaboration (ie, level IV or V) is necessary. New
business models that delink innovation from the volume of sales and unit prices might necessitate collective action, at least by a
core group of countries that bear the major share of R&D costs.

Since we have selected what we believe is the minimum level to drive change, higher levels could also be adopted and be just as successful. FAO=Food and Agriculture
Organization. OIE=World Organisation for Animal Health. LMICs=low-income and middle-income countries. R&D=research and development. BRICS=Brazil, Russia, India,
China, and South Africa.

Table 1: Policies that require international collaboration

infection prevention measures than to create new drugs
that are short-lived. Evidence of eﬀective infection control
interventions is a global public good and should be
made readily available, including summaries appropriate
for policy makers.4
www.thelancet.com Vol 387 January 16, 2016
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Securing access to quality-assured antimicrobials is a
core national responsibility, and policies that countries
can use to improve access are discussed by Mendelson
and colleagues in this Lancet Series.3 The coordinated
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eﬀorts of organisations such as The Global Fund to Fight
AIDS, Tuberculosis and Malaria, Unitaid, and the US
President’s Emergency Plan for AIDS Relief (PEPFAR)
have greatly contributed to improved access to speciﬁc
antimicrobials. However, antibiotics, diagnostics, and
related prevention measures mostly fall outside the
mandate of these organisations. Most ﬁrst-line antibiotics
are inexpensive, costing only pennies per treatment
regimen. However, with the emergence of resistance, the
cost ramps up substantially as second-line and third-line
drugs are needed.14 Donors and governments need to
prioritise universal access to aﬀordable and eﬀective
antimicrobials as a key part of a comprehensive global
solution, thereby contributing to progress towards
universal health coverage.
Many untested alternatives to tackle the issue of antimicrobial access will need to be carefully balanced
against economic incentives for innovation. One option
is for manufacturers to sell their products globally at cost
price while receiving rewards (eg, so-called benchmark
payments) from high-income countries. These payments
would not be tied to unit sales but to compliance with
stipulations such as no promotional marketing of the
product, sales levels in compliance with responsible use
estimates in both human and animal populations, and
equitable access. Another option could be that
manufacturers oﬀer nominal-royalty-bearing licences to
other manufacturers in LMICs, with similar conditions
on the licensees. A third option is to establish
internationally agreed principles related to securing
aﬀordability in low-income countries, where price levels
should be based on what can be achieved by competitive
manufacturing. All of these options will need decisions
that are made in collaboration across countries, with
substantial ﬁnancial support to promote universal access.

Responsible use in and for human beings
Most countries have regulations to ensure drug quality
and responsible marketing, sales, prescriptions, and use
of pharmaceuticals. In paper 4 of this Series, Dar and
colleagues4 have provided speciﬁc examples of how these
regulations can be strengthened and incentives aligned,
including solutions targeting prescribers and reducing
over-the-counter sales. However, an international
consensus is needed to sustain the global eﬀectiveness of
antimicrobials. A potential solution for responsible
marketing and sales is a voluntary, self-regulatory code of
practice by all manufacturers to restrict marketing and
provide transparency on sales and consumption. If such
an international self-regulatory mechanism fails, then
intergovernmental agreements might be necessary.
However, this approach addresses only one side of the
issue. At the same time, physicians should be incentivised
to adhere to clinical guidelines. Regulations and systems
should be strengthened to reduce or eliminate
over-the-counter sales without evidence of appropriate
diagnosis. The existence of over-the-counter antibiotics is
300

justiﬁable only as a short-term solution in low-income
settings with poor access to health-care professionals or
others who could guide responsible use. Ensuring access
to eﬀective antimicrobials, like most other health
priorities, requires a functioning health-care system.
To change professional behaviour, best practices in the
prescribing and use of antimicrobials should be easily
and freely accessible worldwide. Although these
practices, rooted in evidence and surveillance data, are
global public goods, they are time-consuming and
expensive to create and disseminate. This is not to say
that global guidelines on antimicrobial use are desirable;
rather, adjustments need to be made for the national
epidemiological context and resistance proﬁle. However,
global guidance for best practice guidelines should be
coordinated with full transparency.
Some antimicrobials are so medically important that
strong actions such as enforcement mechanisms need
to be taken to ensure their continued eﬀectiveness.
One example is possible limits on over-the-counter sales
of critical classes such as carbapenems. For these drugs,
an option is to learn from the positive experiences
(and avoid the negative results such as those related to
challenges to access) of the controlled drug regimen,
which is rooted in international treaty commitments.15,16
More analyses are needed to explore what aspects of
such an approach can be adopted and what aspects will
need adaptation.

Responsible use in agriculture
Antibiotics are important in treatment of disease in both
human beings and animals, but they are also being used
in healthy animals as growth promoters and a substitute
for good animal husbandry.1,4 In view of the devastating
potential of antimicrobial resistance, all unnecessary use
needs to be curbed. FAO, OIE, and WHO have the
responsibility to raise awareness in their respective
ﬁelds regarding maintenance of eﬀective antimicrobials,
with WHO having the primary mandate to articulate the
public health need for urgent and sustained action. A
need exists for a global agreement on responsible animal
use by elimination of antibiotics used as growth
promoters or as a routine prevention tool through herd
treatment. Global collaboration and enforcement are
necessary to ensure a level playing ﬁeld, since reductions
in access to antimicrobials might have implications on
the running costs of a farm—eg, more oversight of
livestock might be needed.1 Europe banned the use of
antibiotics for growth promotion in 2006.17 The USA
introduced non-compulsory measures in 2013, which
have now resulted in binding withdrawals and label
changes.18 The Chennai declaration aims to achieve an
80% compliance with the rule that antibiotics used for
human treatment will not be used for growth promotion
in food animals.19 In exchange for these prohibitions,
R&D related to animal-speciﬁc solutions, such as
vaccines and alternatives to antibiotics as growth
www.thelancet.com Vol 387 January 16, 2016

Series

promoters, should be encouraged. While these
agreements are being negotiated and implemented, a
medium-term solution could be labelling suggestions to
producers that are already adhering to the best practices.
These foods could command higher prices, similar to
those of organic or local foods. Several major US
restaurant chains are already transitioning to use
chicken and other meats produced without antibiotics
used in human beings.20
International trade law can be an obstacle to reduce or
eliminate the use of antibiotics as growth promoters or
for routine preventive herd treatment, since a formal
national requirement to regulate or ban such use of
antibiotics might be interpreted as a trade barrier
through the World Trade Organization (WTO) rather
than a public health measure.21 Therefore, WTO and
regional trade agreements need to be engaged to ensure
that necessary public health regulations related to
antimicrobial resistance are respected.
Another option is to restrict medically important
antimicrobials to human use only, leaving other classes,
such as ionophores, exclusive to agricultural use. For
example, to begin the process towards reaching a global
consensus, the G20 countries could develop an
agreement in which certain classes of new antimicrobials
and other related health technologies are restricted for
use in either human beings or animals, and incorporate
this agreement into future trade agreements. This
agreement could be coordinated through the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH), a collaboration between the
pharmaceutical industry and the regulatory authorities of
Europe, Japan, and the USA.22 A potential result is that
pharmaceutical manufacturers and animal feed providers
would be less interested to produce an animal variety for
the non-participating countries not only for reputational
reasons but also for the limited proﬁtability of the
remaining markets. Additionally, innovation incentives
for companies could be conditioned on compliance with
these rules in every country. Once compliance exists in
ICH, it could be transitioned to the more comprehensive
International Conference of Drug Regulatory Agencies
organised by WHO.

Innovation
Sustainable access to eﬀective antimicrobials requires
constant innovation, if only to prevent us from slipping
back into a pre-antibiotic era.23 The largest multinational
ﬁnancing initiative so far for antimicrobial R&D is the
Innovative Medicines Initiative (IMI), a public–private
partnership between the European Union and the
European pharmaceutical industry that aims to develop
better and safer drugs. Its New Drugs for Bad Bugs
(ND4BB) programme has invested more than
€600 million in European antimicrobial R&D over
7 years, much of which has been targeted at
www.thelancet.com Vol 387 January 16, 2016

Gram-negative bacteria.24 The European Union’s Joint
Programming Initiative on Antimicrobial Resistance
(JPIAMR) aims to ﬁnd routes for novel antibiotics and
new anti-infectious disease strategies. Their ﬁrst call,
“InnovaResistance”, with a total budget of around
€14 million, was launched in January, 2014, and included
funding opportunities for optimisation of existing
antimicrobials and identiﬁcation of new bacterial targets
and antibiotic compounds.25
Several national initiatives are of a magnitude to have a
global eﬀect, even though their geographical scope is
restricted. An announcement in June, 2014, stated that
the £10 million Longitude Prize would focus on
point-of-care diagnostics, with the creation of a
“cost-eﬀective, accurate, rapid and easy-to-use test for
bacterial infections”.26 A similar diagnostic prize
proposal was announced by the US Government in
September, 2014.27 Some countries have also created
partnerships with individual pharmaceutical companies;
one such example is the 3·5-year collaboration between
AstraZeneca and Singapore’s Agency for Science,
Technology and Research to develop new drugs against
Gram-negative bacterial infections.28 The Biomedical
Advanced Research and Development Authority
(BARDA) in the USA has partnered with GlaxoSmithKline
(GSK) to develop new antibiotics with a potential of
US$200 million for GSK if milestones are met.29 Total
funding from the US National Institutes of Health for
antibacterial resistance averaged US$90 million per year
in 2013 and 2014.
Although an increasing investment is seen in relevant
R&D, present initiatives are still insuﬃcient to ensure
the continued development of new antimicrobials,
diagnostics, or related technologies.30 Most distressingly,
these initiatives are not tied to responsible use policies.
In particular, the existing R&D system closely links
incentives for R&D to the potential price and volume of
sales of the eventual product.3 This system leads to
underinvestment in antibiotic research, high eventual
prices for new products, and lacklustre company support
of antibiotic stewardship.31 There is little assurance that
the new drugs will not be wasted through inappropriate
use. This market failure could be addressed by eﬀorts to
delink company proﬁts from the sales volume for
antimicrobials.30 Since it is a problem that aﬀects all
countries, including those with the ﬁnancial means to
ﬁx it, it should be solvable. Complete global action is
not necessarily required because the actions of a few
high-income countries can have a disproportionately
large global eﬀect, and additional countries will join the
eﬀort in due course.
Therefore, a pledge from a group such as the G20 to
increase their investment in R&D tied to responsible
use and global access stipulations could have a
substantial eﬀect on the antimicrobial R&D landscape.
The new products should be tied to responsible use
provisions to minimise the development of resistance,32
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Subobjective

National level

Global level

Increase availability,
aﬀordability, and
diagnostic targeting of
eﬀective antimicrobials

To achieve appropriate antimicrobial prescribing, LMICs should expand access Global universal access demands a long-term commitment,
to appropriate antimicrobials, especially in rural areas, including provision of with sustained ﬁnancing for all aﬀected countries
laboratory support and increased access to diagnostics

Reduce inappropriate
use

Change professional
behaviour

Stewardship programmes can be eﬀective in encouraging appropriate use of
antibiotics and should be scaled up in both HICs and LMICs where feasible

Increase public
awareness

Change public expectations Public awareness campaigns can be eﬀective when sustained and properly
adapted for local contexts; national campaigns should be encouraged

Global campaigns should be evidence based and their
results assessed

Reduce inappropriate
use in animals

Regulate inappropriate use Antibiotic use for growth promotion or prophylaxis in animals should be
or incentivise appropriate reduced or eliminated; these policies should be coupled with adequate
investment in improved IPCIs in livestock and for other agricultural uses, and
use
with eﬀective mechanisms to remunerate veterinarians and prescribers while
limiting their ability to proﬁt from antimicrobial sales and reorienting their
roles away from commercial gains; further research into the implications of
this policy in LMICs is needed

A coalition of key countries can lead the way to restrict
speciﬁc classes of antimicrobials for human use only;
countries should work with WTO to transition away from
the use of antibiotics for growth promotion or prophylaxis,
using health and SPS exceptions under trade agreements

Strengthen infection
control

IPCIs have chronic underfunding, particularly in the animal
sector, and an investment of several billion US dollars per
year is necessary to upgrade capacity in most LMICs;
global standards for reporting of infections and training of
health workers on hand hygiene and infection control
should be introduced

Access
Expand access

Responsible use
Global guidance should be rooted in evidence and
surveillance data as templates for adaptive national
guidelines on antimicrobial use

Infection control
Reduce need for
antimicrobials

Implementation of eﬀective IPCIs needs to be supported, including
vaccinations, hand hygiene, improved access to water and sanitation, food
safety, and behaviour change

Innovation
National policies should work in concert with global framework eﬀorts, as
New knowledge (R&D) New antibiotics,
antibiotic R&D is a global endeavour
diagnostics, vaccines, and
other relevant technologies

A coalition of key countries can initiate eﬀorts that will
have global results, but investments in new antibiotics
should decouple the price from units consumed, so that
responsible use can be built into the reimbursement and
use of diagnostics

New knowledge (R&D) Increased innovation to
meet the needs of LMICs

National-level research is needed to understand the particular needs of LMICs
with regards to bacterial resistance, such as a rapid point-of-care diagnostic
test that can improve clinical practice in low-resource settings

For antimicrobials, the general recommendations
(including delinkage) of WHO’s Consultative Expert
Working Group on Research and Development: Financing
and Coordination should be acted on

Countries and regions should adopt surveillance systems that best suit their
needs and circumstances, and a programme of harmonisation and
integration of global systems needs to be fostered so between-country
comparisons of antibiotic use and resistance can be more meaningful; the
sentinel surveillance of environmental settings that are likely to contribute to
resistance should be initiated and expanded in HICs and its feasibility
explored in LMICs; for LMICs, an additional focus is to improve monitoring of
drug quality to curb the production of substandard and counterfeit drugs

Establish a global surveillance system to annually obtain
data for and report on the use of antimicrobials and the
prevalence of resistance by country, including eﬀorts to
strengthen laboratory capacity, in both human and animal
populations; LMICs might need ﬁnancial support in these
pursuits; this will also help with a global threat assessment
of risks from antimicrobial resistance

Surveillance
Improved monitoring

Infections and outcomes,
and antimicrobial use;
environmental
surveillance; drug quality

Integration across the policy areas
Evidence base

None

National research programmes need to address unanswered questions and
research gaps, including how to minimise selection of resistance, secure quality
of existing drugs, eﬀectively reduce the prevalence and transmission of
resistant pathogens, and better understand the basic mechanisms of resistance

Systematic reviews of existing policies are needed across
human, animal, and environmental health and the key
areas of resistance control; a standardised framework for
policy examination should be applied and an open-access
central repository of national, regional, and global policy
case studies and assessment developed

Coordination

None

Not applicable

Better global coordination and ﬁnancing mechanisms are
required—eg, informal country coalitions, a pan-UN
intergovernmental agency, or an international treaty

LMICs=low-income and middle-income countries. HICs=high-income countries. WTO=World Trade Organization. SPS=sanitary and phytosanitary. IPCIs=infection prevention and control interventions.
R&D=research and development.

Table 2: Overall recommendations for policy interventions

which would probably include agreement by
manufacturers to not promote the products in exchange
for payments that are not based on unit sales. Moreover,
the innovators would need to ensure that their new
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products are globally available, as discussed in the
section on universal access. These stipulations would
be negotiated and enforced contractually between
innovators and high-income countries.
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The global action plan to combat antimicrobial
resistance
In this Lancet Series, we have identiﬁed a set of
recommendations across the ﬁve policy areas both for
individual countries and globally (table 2). Each one of
these policy recommendations could be implemented
individually but might work at cross purposes to each
other as we have described. To create an eﬀective and
sustainable path forward, these recommendations
should be implemented in concert.
At the 68th World Health Assembly in May, 2015, a
global action plan to combat antimicrobial resistance was
approved by Member States.33 This global action plan
provides the framework for national plans to combat
antimicrobial resistance, in which Member States need to
deﬁne timelines, targets, and activities, and identify
particular areas that need technical support from WHO
and other partners. Successful implementation depends
on Member States playing their crucial part to fulﬁl
commitments, mobilise funding, implement appropriate
surveillance programmes, build and support the necessary
infrastructure (eg, laboratories), and introduce and
enforce appropriate legislation.
The global action plan also gives WHO a clear
mandate, leadership, and coordinating role, since WHO
represents a natural platform for global health solutions
that require improved communication and coordination
among countries, including those of surveillance,
infection control, and guidance on stewardship
(table 1).3,4 Although many of the needed global actions
have long been recognised, implementation by Member
States, WHO, or other actors has been insuﬃcient. A
report from the WHO Secretariat concluded that past
World Health Assembly resolutions, reports, and calls
for mobilisation have not resulted in widely accepted
global actions.34 This inertia could probably be explained
by various reasons—eg, insuﬃcient ﬁnancing, strong
lobbying on behalf of diverse stakeholders, free-riding

tendencies, and so on. Progress depends on convincing
individual countries of the eﬀect of local actions, and
ﬁnding suitable solutions and the necessary support in
this endeavour.3,4

National accountability and indicators
The great diﬀerentiator between the global action plan
and past WHO resolutions has to be strong national
accountability mechanisms to ensure that Member
States create and implement their own plans to combat
antimicrobial resistance. These mechanisms are likely to
be a mixture of incentives and enforcement measures
based on measurable indicators. For LMICs, external
ﬁnancing might be predicated upon development of a
national plan to combat antimicrobial resistance and
eventually report against a set of agreed indicators.
Compliance to national plans can be reinforced by widely
reporting results in plain language so that local media is
engaged in national progress (see table 3 for examples of
national indicators).
WHO’s South-East Asia Region is to be commended
for developing its own indicators in 2010.35 Whereas this
policy-oriented approach uses process indicators, we
suggest data-driven targets, such as annual per-person
antibiotic consumption, so that the indicators do not
need to change when new national goals are proposed.
Almost all of our suggested indicators (table 3) report
against several policy areas. For example, annual
per-person antibiotic consumption can report progress
both in a country with insuﬃcient access to antibiotics
and in a country with overuse of antibiotics, showing that
interlinkages exist between the policy areas.
Even though we suggest only six indicators, we
believe that few countries can report on all six of them
at present. Improved surveillance systems will need to
be implemented; although such systems are costly and
time-consuming, they are a precondition to establish
accountability. For low-income countries, such systems

Indicator

Rationale

Surveillance

IHR’s existing laboratory indicator (ie, Laboratory services) is
available to test for priority health threats

Identify laboratory capacities that need improvement, including
external resources

Surveillance and access

Annual antibiotic consumption by drug and age

Match against national goals to suggest change in antibiotic
consumption in speciﬁed populations

Surveillance and infection
control

Annual incidence of antimicrobial resistance by pathogen and Identify which pathogens are being tracked and progress towards
age (ie, a national threat assessment)
controlling the emergence of resistance over time

Surveillance and
responsible use

Annual percentage of total antibiotic consumption in human
use and agriculture by drug; in agriculture, report by animal
species, drug, and purpose

Quantify the split of antibiotic consumption between human and
non-human use, and reduce non-human use

Surveillance, responsible
use, and access

Annual consumption of restricted-use antibiotics

Show the overconsumption or underconsumption of antibiotics
deemed to be of critical medical importance

Innovation and access

New molecular entities submitted to and approved by
regulatory authorities, by therapeutic area per year, with a
focus on drugs targeting priority pathogens identiﬁed
through threat assessments

Compare trends in global innovation of new antimicrobials,
vaccines, and diagnostics, and access to these innovations
in LMICs

IHR=International Health Regulations. LMICs=low-income and middle-income countries.

Table 3: Potential national indicators in the WHO global action plan, by policy area
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Beneﬁts

Costs

All countries

Greatly improved global health; avoidance of the costs of a
post-antimicrobial era (eg, inability to perform routine
surgeries and treat common infections); avoidance of the
inevitable closure of borders and restraints on travel and
trade that would follow from rampant epidemics

Increased investments to protect and sustain
eﬀectiveness of antimicrobials

LMICs

Enhanced access to aﬀordable antimicrobials, including
subsidised prices when necessary; ﬁnancial and technical
support for capacity strengthening in surveillance,
responsible use, and infection control

Increased investments in health system capacities for
surveillance, responsible use, and infection control

Emerging economies

Increased markets for producers of antimicrobials

Increased investments in and enforcement of regulatory
capacities, and investments in health system capacities
for surveillance, responsible use, and infection control

High-income countries

Sustainability of existing antimicrobials and the medical
care system that depends on them

Increased investments in innovation through R&D and
aggregate reimbursement or delinked payments to
producers; support to LMICs for capacity building

Innovative pharmaceutical
companies

Increased rewards and incentives for innovation; decreased
marketing expenses; reduced risk and structured rewards
through delinked payments

Adherence to additional marketing regulations and
cooperation on global public health goals

Generic pharmaceutical companies

Opportunity to manufacture antimicrobials on licence
for LMICs

Adherence to additional marketing regulations, quality
assurance, and other stipulations

Agriculture

A level playing ﬁeld with global regulations regarding
antibiotic use in agriculture, especially for meat production

Increased investments in animal health and welfare,
including alternatives to antibiotics

R&D=research and development. LMICs=low-income and middle-income countries.

Table 4: Beneﬁts and costs accrued by a coherent package

might require long-term ﬁnancing commitments from
donors, tied to measurable results and careful
incremental and scalable implementation, potentially
starting ﬁrst with public hospitals and clinics and
expanding from there.

A coherent package of solutions
These interlinkages between policy areas complicate
implementation, since each of the areas requires real
eﬀort for some actors, thereby blocking unanimous
support. In other cases, beneﬁts for individual groups of
actors are insuﬃcient to warrant unilateral action.
Among the ﬁve policy areas considered in this Series, we
have shown that three—namely, access, responsible use,
and innovation—will need collaborative global decisions
or collective global action (table 1). We believe that the
best way forward towards an international agreement
on these three policy areas is not to tackle them
independently but as one coherent package. These policy
areas should be linked to deliver a sustainable and
cost-eﬀective solution—eg, by substantially increased
coordination of public sector R&D funding and incentives
for innovation, both tied to stipulations of minimal
marketing and to licensing intellectual property to
manufacturers in LMICs who are also bound by
responsible use provisions.
If the coherent package is constructed carefully, most
of the diverse range of stakeholders will beneﬁt from a
long-term solution securing eﬀective antimicrobials
(table 4). High-income countries will need to pay most of
the innovation bill but will, in return, protect their
populations from infections that cross borders. More
304

equitable access will be achieved for all countries in
return for better infection control and stewardship.
Low-income countries will get support for capacity
building and be assured aﬀordable and appropriate
antimicrobials. R&D-based pharmaceutical companies
will receive higher and more predictable rewards for
antimicrobial innovations than they do at present, and
generic-drug manufacturers will have opportunities to
produce quality-assured drugs under licence. Restrictions
in antibiotic use in agriculture will promote global fair
competition, since all producers have to abide by the
same public health measures, supported by research for
alternatives to agricultural antibiotics.

Achieving collective action
The responsibility to implement this coherent package
needs to rest on suﬃciently funded and empowered
authorities. An institutional base and a forum for
negotiation are necessary to ensure progress. WHO
alone will be unable to facilitate the implementation of
this package, and a multisectoral response—eg, from a
UN-appointed entity or one structured through a
coalition of like-minded, proactive countries and actors—
will be essential. Such a response can be rooted in
international law or be an institutional solution
originating from a top-level political declaration. An
internationally binding agreement could be the end
result after substantial momentum is achieved in
national implementation.
An international legal mechanism can be negotiated at
WHO or the UN General Assembly. One weakness of a
treaty is the need to cover most or all nations through an
www.thelancet.com Vol 387 January 16, 2016

Series

opt-in instrument that needs ratiﬁcation by Member
States to become legally binding. If WHO is used as a
forum, another option is to take advantage of its
constitutional power to adopt regulations under Article 21.
Such regulations are opt-out instruments that come into
force immediately for all Member States after their
adoption by the World Health Assembly.36 Any legal
mechanism at WHO should be paired with a sister
agreement at the FAO and OIE to ensure compatibility
across sectors.
An international agreement can also be negotiated by a
subset of countries and then gradually adopted through
incremental processes, such as the Anti-Personnel
Mine Ban Convention and the Convention on Cluster
Munitions. The advantage of starting with a small group
of countries and then expanding is that the process can
be swifter, more decisive, and of lower risk than if many
countries are involved.36 Once a critical mass of countries
has signed on, universal agreement can be sought as
discussed previously.
An international legal mechanism can contain
provisions for technical and ﬁnancial support for capacity
building. One example is the Multilateral Fund for the
Implementation of the Montreal Protocol, which assists
LMICs to implement measures protecting the ozone
layer.37 However, it would be diﬃcult for an international
legal mechanism itself to mandate binding ﬁnancial
obligations representing large innovation investments,
as shown in debates surrounding the ﬁnancing of R&D
for neglected diseases.38 Perhaps lessons can be learnt
from international scientiﬁc collaborations such as the
European Organization for Nuclear Research and the
International Space Station.
Another possibility other than a legally binding
instrument would be to create a UN agency, similar to
UNAIDS, that is mandated with implementation of the
coherent package. Led by high-level individuals, this
agency could work through the political process and
media to elucidate and persuade governments, health
professionals, and the public, in a similar process to the
Millennium Development Goals, but with a more formal
organisational structure. This agency could work with
partners such as GAVI Alliance and The Global Fund to
Fight AIDS, Tuberculosis and Malaria to implement
a plan of expanded appropriate access to eﬀective
antimicrobials and vaccines to reduce the need for
such drugs.

Conclusion
Interdependent and interconnected problems need
integrated solutions. Concurrent expansion of access
and reduction of inappropriate use are necessary, and
innovation rewards have to be delinked from unit-based
sales revenues so that payments are not generally based
on the number and price of drugs sold. Securing
eﬀective antimicrobials calls for systemic and interdependent solutions.39,40
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Global public goods, such as new antimicrobials,
diagnostics, and treatment guidelines, should be
secured through joint contributions and collaboration.
Mobilisation of global solidarity will be necessary to
secure resources and ﬁnancing for universal access and
for national capacities for surveillance, responsible use,
and infection control. Coordination of these functions
will require not only leadership and political will, but
also strong implementation and potentially enforcement
mechanisms.41
Fortunately, securing eﬀective antimicrobials has
ﬁnally gained a place on the global agenda. Member
States have endorsed WHO’s global action plan to
combat antimicrobial resistance.42 The USA has
launched a national strategy and an action plan to
address antibiotic resistance, which awaits Congressional
action.43 The Transatlantic Task Force on Antimicrobial
Resistance between the USA and the European Union
has put forward a series of recommendations for joint
action.23 South Africa has agreed to an antimicrobial
resistance national strategy framework.44 The UK has
initiated an independent review on antimicrobial
resistance, which stated that development of ten new
highly eﬀective drugs in the next decade would cost less
than US$25 billion (or 0·03% of global gross domestic
product [GDP]).45,46 A recent report to the Nordic Council
of Ministers47 recommended a global investment of
0·005% of annual global GDP over a 5-year period.
There has also been a call for an intergovernmental
antimicrobial panel, like the UN Intergovernmental
Panel on Climate Change, which can synthesise and
organise the available evidence to inform adoption and
implementation of national policies.48 However, such a
panel might be unnecessary, since a scientiﬁc consensus
has already been reached regarding actions needed to
secure eﬀective antimicrobials.
Global actions need to integrate access to eﬀective
antimicrobials with infection prevention, responsible
use of existing antimicrobials, surveillance, and
innovation. These actions need to bridge the realms of
public health, agriculture, animal husbandry, and trade.
We have proposed a set of national and global
recommendations (table 2) rooted in the analyses of
this Lancet Series.1–4 Recommendations should be
supported by strong implementation mechanisms that
incorporate incentives for leaders to act on them,
institutions that bring edicts into eﬀect, and interests
advocating their prioritisation.36,49 This implementation
should lead to a new global institutional arrangement, either an international legal mechanism or a
UN agency.
Deadly bacterial pathogens are present in every country
of the world, and new resistant pathogens are evolving
every day. We need to secure and expand our arsenal of
antimicrobials. Therefore, we urge world leaders to
consider, commit to, and champion implementation of
these recommendations.
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